IceCure Medical : Caesarea & Cleveland.

quoted in today's UK DAILY MAIL


IceCure Medical, Inc.wirby@icecure-medical.com

ISRAEL’S ICECURE MEDICAL OPENS U.S. HEADQUARTERS IN CLEVELAND
CAESAREA, ISRAEL and CLEVELAND, OH – IceCure Medical LTD., an Israeli medical device company providing physicians with minimally-invasive, office-based, cryoablation solutions for women’s health, will open its U.S. headquarters on June 1, 2011 in Cleveland’s Global Cardiovascular Innovation Center (GCIC).
"The unique infrastructure for growing biomedical companies, the support we received from many
organizations, and the progressive health care environment that includes world-class institutions such as the
Cleveland Clinic and University Hospitals Case Medical Center, led us to choose Cleveland for our US
operations,” said Hezi Himelfarb, CEO of IceCure Medical.
The IceCure Cleveland-based staff will be launching U.S. marketing and sales of the new state-of-the-art
IceSense3™ cryoablation system. The IceSense3 technology treats benign breast growths through freezing, as a quick, safe and successful alternative to invasive surgery. “We are thrilled to offer a patient-friendly, inoffice, minimally invasive treatment for benign breast disease,” said Mr. Himelfarb.

“We are pleased that IceCure has selected Ohio as the location for its US operations," said Jim Leftwich, the
Director of the Ohio Department of Development. "The State of Ohio has strongly supported the development
of a vibrant biomedical innovation environment."
“The Health Tech Corridor builds on one of our region's economic strengths and is an international destination
for medical technology companies. Cleveland’s ability to attract companies like IceCure and help them develop
their business is essential for the growth and success of the area,” said Mayor Frank G. Jackson. “We welcome
them home to the City of Cleveland.”
“This is a testament to how well Northeast Ohio’s economic development partners work together to attract
leading organizations into our growing biomedical cluster,” said Tom Waltermire, CEO of Team Northeast
Ohio (NEO). “In the future, we anticipate that IceCure Medical will bring 15 highly skilled jobs and roughly $1
million in annual payroll into the Cleveland Plus region.”
“IceCure Medical has strong growth potential,” said Baiju R. Shah, president and CEO of BioEnterprise, “It's a
testament to the state’s and region’s initiatives to attract foreign high-tech firms and support their business
growth in the U.S, including Israeli companies such as MDG Medical, NI Medical, and Simbionix, that IceCure
has selected Cleveland.”
Supported by the Ohio Capital Fund, Bridge Investment Fund LP has been instrumental in supporting Israeli
companies with innovative technology set up operations in Cleveland. “Bridge works closely with its portfolio
companies to address their specific needs to grow in the US market, and we look forward to IceCure opening
shop here,” said Michael Goldberg, managing director of the Fund.
IceCure Medical will lease space in GCIC’s 50,000 sq. ft. facility adjacent to the Cleveland Clinic, which
“provides close proximity to world-class clinical researchers and clinicians along with extensive facility and
business support services,” according to GCIC Managing Director, Mark Low.
About IceCure Medical Ltd
IceCure Medical Ltd. Is a publicly traded medical device company (TASE: ICCM), focusing on minimally
invasive, office-based, cryoablation solutions for treating women’s tumors. The company was founded in 2006
with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio. For more information, visit:
www.icecure-medical.com.